Senior Associate Counsel (Corporate Strategy Team)

Immix Biopharma (Nasdaq: IMMX); Los Angeles (CA); Sur place; USD 180 000 - 240 000; Plein temps

Résumé du poste

Immix Biopharma, Inc. is seeking a detail-oriented Senior Associate Counsel to support the Corporate Strategy Team. The role focuses on contracting, regulatory document creation, and equity/debt capital markets and M&A work in a growing biotech environment.

You will work closely with regulatory, strategy, and finance teams to ensure seamless execution of company initiatives across all verticals and assist in investor communications and fundraising activities as ImmixBio expands.

Qualifications

• 1–3 years at a top law firm focused on equity/debt capital markets or M&A.
• JD or equivalent; US Bar eligibility preferred for practice.
• Strong drafting and regulatory documentation skills.

Responsabilités

• Oversee contracting and regulatory document creation across regimes.
• Collaborate with regulatory, strategy, and finance teams on initiatives.
• Contribute to company strategy discussions and execution.
• Participate in investor relations and fundraising activities.
• Draft investor presentations and communications materials.

Connaissances

ECM/DCM/M&A experience

Transaction focus

Formation

Juris Doctor (JD)

US Bar eligibility or LLM + Bar

Description du poste

Senior Associate Counsel (Corporate Strategy Team)

Our Values

We are looking for a detail-oriented, motivated and focused JD with a handful of years of transaction (equity, debt capital markets and/or mergers & acquisitions) experience who is looking to participate in the expansion and growth of a biotechnology company.

What You Will Do

• Oversee contracting, regulatory document creation and submission across various regulatory regimes
• Work closely with regulatory, strategy, and finance teams to ensure seamless execution of company strategy initiatives across all verticals
• Contribute and participate in company strategy discussion
• Participate in investor relations and fundraising activities
• Contribute to drafting and crafting investor presentation and communications materials

What We Look For

• 1-3 years of work experience with a premier law firm focused on executing equity capital markets, debt capital markets, and or mergers & acquisitions transactions
• JD or equivalent (US LLM +Bar if foreign law degree)

Who we are …

Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a “digital filter” that is designed to filter out non‑specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi‑center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a potentially registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.